Recruiting
Phase 1
Phase 2

VT3989

Sponsor:

Vivace Therapeutics, Inc

Code:

NCT04665206

Conditions

Solid Tumor, Adult

Mesothelioma

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VT3989

Nivolumab & Ipilimumab

Osimertinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Vivace Therapeutics, Inc on 2025-08-11.